Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering, Physiology and Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, 3775 University Street, Montreal, QC, H3A 2B4, Canada Faculty of Dentistry, McGill University, Montreal, QC, H3A 2B2, Canada.
Biomedical Technology and Cell Therapy Research Laboratory, Departments of Biomedical Engineering, Physiology and Artificial Cells and Organs Research Center, Faculty of Medicine, McGill University, 3775 University Street, Montreal, QC, H3A 2B4, Canada.
Benef Microbes. 2014 Dec;5(4):447-60. doi: 10.3920/BM2014.0011.
Oral diseases, specifically dental caries and periodontal disease, are characterised by increases in pathogenic microorganisms, increased demineralisation and increased inflammation and levels of inflammatory markers. Despite the therapeutic strategies, oral diseases have elevated prevalence rates. Recent work has demonstrated that probiotic bio-therapeutics can decrease oral pathogen counts, including caries-causing Streptococcus mutans and oral inflammation. The aim of this work was to investigate putative probiotic bacteria, selected for S. mutans inhibition and for their oral health-promoting characteristics. The probiotic bacteria were screened for S. mutans inhibition, probiotic bacteriocin activity, salivary pH modulation, probiotic nutrient (sucrose) competition, probiotic co-aggregation with S. mutans, bacterial attachment to oral epithelial keratinocytes, bacterial nitric oxide production and bacterial antioxidant activity. The results indicate that Lactobacillus reuteri strains NCIMB 701359, NCIMB 701089, NCIMB 702655 and NCIMB 702656 inhibited S. mutans to non-detectable levels (<10 cfu/ml). L. reuteri strains also demonstrated the highest antioxidant capacity of the tested strains (7.73-13.99 µM Trolox equivalents), suggesting their use as both caries and periodontal disease therapeutics. Although Lactobacillus fermentum NCIMB 5221 inhibited S. mutans at lower levels, it significantly buffered the pH (4.18) of saliva containing S. mutans, co-aggregated with S. mutans (10.09%), demonstrated high levels of sucrose consumption (138.11 mM) and successfully attached to gingival epithelial cells (11%). This study identified four L. reuteri strains and one L. fermentum strain to be further investigated as oral disease biotherapeutics.
口腔疾病，特别是龋齿和牙周病，其特征是致病菌数量增加、脱矿加剧以及炎症和炎症标志物水平升高。尽管采用了治疗策略，口腔疾病的患病率仍然居高不下。最近的研究表明，益生菌生物治疗剂可以减少口腔病原体的数量，包括致龋变形链球菌和口腔炎症。本研究旨在筛选出具有抑制变形链球菌作用和促进口腔健康特性的潜在益生菌。我们筛选了益生菌对变形链球菌的抑制作用、益生菌细菌素活性、唾液 pH 值调节、益生菌营养（蔗糖）竞争、益生菌与变形链球菌的共聚集、细菌对口腔上皮角质细胞的黏附、细菌产生一氧化氮和细菌抗氧化活性。结果表明，乳杆菌菌株 NCIMB 701359、NCIMB 701089、NCIMB 702655 和 NCIMB 702656 可将变形链球菌抑制到无法检测的水平（<10 cfu/ml）。乳杆菌菌株还表现出测试菌株中最高的抗氧化能力（7.73-13.99 µM Trolox 当量），表明它们可用于龋齿和牙周病的治疗。虽然发酵乳杆菌 NCIMB 5221 对变形链球菌的抑制作用较低，但它能显著缓冲含有变形链球菌的唾液的 pH 值（4.18），与变形链球菌共聚集（10.09%），消耗大量蔗糖（138.11 mM），并成功黏附于牙龈上皮细胞（11%）。本研究鉴定了 4 株乳杆菌和 1 株发酵乳杆菌菌株，将进一步作为口腔疾病的生物治疗剂进行研究。
